Patricia M Flynn1, Taha E Taha2, Mae Cababasay3, Mary Glenn Fowler4, Lynne M Mofenson5, Maxensia Owor6, Susan Fiscus7, Lynda Stranix-Chibanda8, Anna Coutsoudis9, Devasena Gnanashanmugam10, Nahida Chakhtoura11, Katie McCarthy12, Cornelius Mukuzunga13, Bonus Makanani14, Dhayendre Moodley15, Teacler Nematadzira16, Bangini Kusakara16, Sandesh Patil17, Tichaona Vhembo16, Raziya Bobat18, Blandina T Mmbaga19, Maysseb Masenya20, Mandisa Nyati21, Gerhard Theron22, Helen Mulenga23, Kevin Butler3, David E Shapiro3. 1. Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 3. Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, MA. 4. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD. 5. Elisabeth Glaser Pediatric AIDS Foundation, Washington, DC. 6. Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda. 7. Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC. 8. Department of Paediatrics and Child Health, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe. 9. Department of Pediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa. 10. Division of AIDS, National Institute of Allergy and Immunology, National Institutes of Health, Bethesda, MD. 11. Maternal and Pediatric Infectious Disease Branch, Eunice Kennedy Shriver Institute of Child Health and Human Development, National Institutes of Health, Rockville, MD. 12. FHI 360, Durham, NC. 13. University of North Carolina-Lilongwe, Lilongwe, Malawi. 14. Department of Obstetrics and Gynecology, College of Medicine, University of Malawi, Blantyre, Malawi. 15. Department of Obstetrics and Gynecology, Centre for the AIDS Programme of Research in South Africa and School of Clinical Medicine, College of Health Sciences, University of KwaZulu Natal, Durban, South Africa. 16. University of Zimbabwe-University of California, San Francisco, Harare, Zimbabwe. 17. Department of Obstetrics and Gynecology, Byramjee Jeejeebhoy Government Medical College and Johns Hopkins Clinical Trials Unit, Pune, India. 18. Department of Pediatrics and Child Health, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. 19. Department of Pediatrics, Kilimanjaro Christian Medical Centre, Moshi, Tanzania. 20. Wits Reproductive Health and HIV Institute, Johannesburg, South Africa. 21. Perinatal HIV Research Unit, Chris Baragwanath Hospital, Johannesburg, South Africa. 22. Department of Obstetrics and Gynecology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 23. George Clinic, Centre for Infectious Diseases Research in Zambia, Lusaka, Zambia.
Abstract
BACKGROUND: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of mother-to-child transmission throughout the breastfeeding period. SETTING: Fourteen sites in Sub-Saharan Africa and India. METHODS: A randomized, open-label strategy trial was conducted in HIV-1-infected women with CD4 counts ≥350 cells/mm (or ≥country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns. Randomization at 6-14 days postpartum was to mART or infant nevirapine (iNVP) prophylaxis continued until 18 months after delivery or breastfeeding cessation, infant HIV-1 infection, or toxicity, whichever occurred first. The primary efficacy outcome was confirmed infant HIV-1 infection. Efficacy analyses included all randomized mother-infant pairs except those with infant HIV-1 infection at entry. RESULTS:Between June 2011 and October 2014, 2431 mother-infant pairs were enrolled; 97% of women were World Health Organization Clinical Stage I, median screening CD4 count 686 cells/mm. Median infant gestational age/birth weight was 39 weeks/2.9 kilograms. Seven of 1219 (0.57%) and 7 of 1211 (0.58%) analyzed infants in the mART and iNVP arms, respectively, were HIV-infected (hazard ratio 1.0, 96% repeated confidence interval 0.3-3.1); infant HIV-free survival was high (97.1%, mART and 97.7%, iNVP, at 24 months). There were no significant differences between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-threatening, or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, respectively). CONCLUSIONS: Both mART and iNVP prophylaxis strategies were safe and associated with very low breastfeeding HIV-1 transmission and high infant HIV-1-free survival at 24 months.
RCT Entities:
BACKGROUND: No randomized trial has directly compared the efficacy of prolonged infant antiretroviral prophylaxis versus maternal antiretroviral therapy (mART) for prevention of mother-to-child transmission throughout the breastfeeding period. SETTING: Fourteen sites in Sub-Saharan Africa and India. METHODS: A randomized, open-label strategy trial was conducted in HIV-1-infectedwomen with CD4 counts ≥350 cells/mm (or ≥country-specific ART threshold if higher) and their breastfeeding HIV-1-uninfected newborns. Randomization at 6-14 days postpartum was to mART or infantnevirapine (iNVP) prophylaxis continued until 18 months after delivery or breastfeeding cessation, infantHIV-1 infection, or toxicity, whichever occurred first. The primary efficacy outcome was confirmed infantHIV-1 infection. Efficacy analyses included all randomized mother-infant pairs except those with infantHIV-1 infection at entry. RESULTS: Between June 2011 and October 2014, 2431 mother-infant pairs were enrolled; 97% of women were World Health Organization Clinical Stage I, median screening CD4 count 686 cells/mm. Median infant gestational age/birth weight was 39 weeks/2.9 kilograms. Seven of 1219 (0.57%) and 7 of 1211 (0.58%) analyzed infants in the mART and iNVP arms, respectively, were HIV-infected (hazard ratio 1.0, 96% repeated confidence interval 0.3-3.1); infant HIV-free survival was high (97.1%, mART and 97.7%, iNVP, at 24 months). There were no significant differences between arms in median time to breastfeeding cessation (16 months) or incidence of severe, life-threatening, or fatal adverse events for mothers or infants (14 and 42 per 100 person-years, respectively). CONCLUSIONS: Both mART and iNVP prophylaxis strategies were safe and associated with very low breastfeeding HIV-1 transmission and high infantHIV-1-free survival at 24 months.
Authors: Charles S Chasela; Michael G Hudgens; Denise J Jamieson; Dumbani Kayira; Mina C Hosseinipour; Athena P Kourtis; Francis Martinson; Gerald Tegha; Rodney J Knight; Yusuf I Ahmed; Deborah D Kamwendo; Irving F Hoffman; Sascha R Ellington; Zebrone Kacheche; Alice Soko; Jeffrey B Wiener; Susan A Fiscus; Peter Kazembe; Innocent A Mofolo; Maggie Chigwenembe; Dorothy S Sichali; Charles M van der Horst Journal: N Engl J Med Date: 2010-06-17 Impact factor: 91.245
Authors: Mary G Fowler; Min Qin; Susan A Fiscus; Judith S Currier; Patricia M Flynn; Tsungai Chipato; James McIntyre; Devasena Gnanashanmugam; George K Siberry; Anne S Coletti; Taha E Taha; Karin L Klingman; Francis E Martinson; Maxensia Owor; Avy Violari; Dhayendre Moodley; Gerhard B Theron; Ramesh Bhosale; Raziya Bobat; Benjamin H Chi; Renate Strehlau; Pendo Mlay; Amy J Loftis; Renee Browning; Terence Fenton; Lynette Purdue; Michael Basar; David E Shapiro; Lynne M Mofenson Journal: N Engl J Med Date: 2016-11-03 Impact factor: 91.245
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Anna Coutsoudis; Francois Dabis; Wafaie Fawzi; Philippe Gaillard; Geert Haverkamp; D Robert Harris; J Brooks Jackson; Valerie Leroy; Nicolas Meda; Philippe Msellati; Marie-Louise Newell; Ruth Nsuati; Jennifer S Read; Stefan Wiktor Journal: J Infect Dis Date: 2004-05-26 Impact factor: 5.226
Authors: Michael J Boivin; Limbika Maliwichi-Senganimalunje; Lillian W Ogwang; Rachel Kawalazira; Alla Sikorskii; Itziar Familiar-Lopez; Agatha Kuteesa; Mary Nyakato; Alex Mutebe; Jackie L Namukooli; MacPherson Mallewa; Horacio Ruiseñor-Escudero; Jim Aizire; Taha E Taha; Mary G Fowler Journal: Lancet HIV Date: 2019-05-20 Impact factor: 12.767
Authors: Pamela M Murnane; Peter Bacchetti; Judith S Currier; Sean Brummel; Hideaki Okochi; Nhi Phung; Alexander Louie; Karen Kuncze; Risa M Hoffman; Teacler Nematadzira; Dean K Soko; Maxensia Owor; Friday Saidi; Patricia M Flynn; Mary G Fowler; Monica Gandhi Journal: AIDS Date: 2019-08-01 Impact factor: 4.177
Authors: Sufia Dadabhai; Bonus Makanani; Nan Hua; Rachel Kawalazira; Frank Taulo; Luis Gadama; Taha E Taha Journal: Int J Gynaecol Obstet Date: 2020-03-02 Impact factor: 3.561
Authors: Betty Mogesi Samburu; Judith Kimiywe; Sera Lewise Young; Elizabeth W Kimani-Murage; Frederick Murunga Wekesah; Milka Njeri Wanjohi; Peter Muriuki; Nyovani Janet Madise; Paula L Griffiths Journal: Int Breastfeed J Date: 2021-05-08 Impact factor: 3.461
Authors: Catherine N Le; Paula Britto; Sean S Brummel; Risa M Hoffman; Jonathan Z Li; Patricia M Flynn; Taha E Taha; Anne Coletti; Mary Glenn Fowler; Ronald J Bosch; Rajesh T Gandhi; Karin L Klingman; James A McIntyre; Judith S Currier Journal: AIDS Date: 2019-11-15 Impact factor: 4.177
Authors: Konstantia Angelidou; Mary Glenn Fowler; Pat Flynn; Anne Coletti; Katie McCarthy; Renee Browning; James McIntyre; Sean S Brummel; David E Shapiro; Camlin Tierney Journal: Clin Trials Date: 2020-03-19 Impact factor: 2.486